Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
Abstract
B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19 + B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor- EGFP cassette, which yielded site-specific integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.
Overview
CoChat Summary
TL;DR
This paper reports optimized CRISPR/Cas9 genome engineering of primary human B cells using CD40L/IL4 expansion, electroporation of RNPs or Cas9 mRNA, and AAV6 donor delivery. It achieves >70% CD19 knockout and site-specific AAVS1 integration reported up to 25%, with results peaking at 18 ± 4% at MOI 250,000.
Key findings
- CD19+ B cells expanded in culture, with the IgD+ IgM+ CD27− naïve subset increasing from 35 ± 6% to 81 ± 2% by day 7 and remaining over 80%; total B cells expanded 10-fold.
- B cells became permissive to mRNA electroporation by day 3, peaking at day 7; naïve B cell EGFP transfection was 41 ± 8% on day 3, 58 ± 9% on day 7, and 52 ± 7% on day 10.
- Chemically modified sgRNA with Cas9 protein or Cas9 mRNA induced >70% CD19 indel formation (74 ± 19% and 72 ± 4%) and >70% CD19 protein loss (75 ± 11% and 72 ± 13%); Alt-R gRNA with Cas9 protein gave 65 ± 9% indels and 72 ± 11% CD19 knockout, while Alt-R gRNA with Cas9 mRNA gave no editing. RNP-treated cells showed better post-editing expansion (529,000 ± 150,000 cells, 75 ± 4% viability) than Cas9 mRNA-treated cells (130,000 ± 111,000 cells, 59 ± 18% viability).
- AAV6 delivered a splice acceptor-EGFP donor to AAVS1, yielding EGFP expression at all MOIs tested and peaking at 18 ± 4% with MOI 250,000; the abstract and discussion report site-specific integration up to 25%. RNPs targeting MYC and IGH created individual DSBs at 78.0% and 56.6%, and the t(8;14) translocation was detected only when both RNPs were combined.
Methods
- Primary human PBMCs from de-identified healthy donors were obtained by leukapheresis; CD19+ B cells were isolated by immunomagnetic negative selection and expanded with CD40L multimer and IL4.
- Electroporation used the Neon Transfection System at 1400 V, 10 ms, 3 pulses; CRISPR formats included chemically modified sgRNA or Alt-R crRNA:tracrRNA with Cas9 protein or Cas9 mRNA. Editing was measured by TIDE and flow cytometry.
- AAV6 was used to deliver a splice acceptor-EGFP cassette with 500 bp homology arms to the AAVS1 safe harbor site; integration was assessed by EGFP expression and junction PCR. Statistical analysis used one-way ANOVA with p < 0.05.
Limitations
- The paper does not include a formal limitations section. It states that further work is required to fully realize therapeutic potential and that initial t(8;14) cultures showed no obvious transformed properties, with transformation to be studied in greater depth.
- Evident from the text: no in vivo engraftment, plasma cell maturation, antibody secretion, or therapeutic efficacy data are shown; these are discussed only as future applications.
- Evident from the text: no off-target analysis is reported, sample sizes are small (n = 2–6 in figures), and the AAVS1 integration efficiency varies between the reported peak of 18 ± 4% in results and “up to 25%” in the abstract/discussion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 36 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“B cell numbers remain roughly constant for 7 days before beginning to rapidly expand (Fig. 1A).”
§ Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease > Results > Naïve B cells are activated and expanded in culture with CD40L and IL4
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Plasmablasts and Plasma cells were undetectable at all time points (data not shown).”
§ Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease > Results > Naïve B cells are activated and expanded in culture with CD40L and IL4
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While all conditions tested achieved over 50% transfection efficiency as measured by GFP expression and over 80% post electroporation cell viability, Condition 12 resulted in the optimal combination of EGFP+ frequency, cell viability, and post-electroporation cell expansion (Fig. 2B).”
§ Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease > Results > Multiple electroporation conditions allow for efficient transfection of activated B cells
plainstates an associationn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No EGFP expression was detected in any B cell subset following transfection on day 0 and day 1 post-activation, indicating a lack of permissiveness to mRNA transfection at these time points.”
§ Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease > Results > B cells become permissive to transfection with mRNA by day 3
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observed band matches the size of the predicted 295 bp amplification product.”
§ Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease > Results > CRISPR/Cas9 RNPs can be used to induce chromosomal translocations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 47 claims and to verify the 19 references still open.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Along these lines, three independent groups introduced RNP complexes into human B cells that had been pre-activated with a cocktail of cytokines [8–10].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [10]
In the citing paper
“Results from these studies suggested that the efficiency of gene editing correlated with the level of B cell stimulation prior to nucleofection of the RNP complexes.”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [10]
Citations
Cites
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Humoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,245
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Hockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R. C., Katibah, G. E., Amora, R., Boydston, E. A., Zeitler, B., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1562 · Cited by 1,056
Competence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature Reviews Immunology · doi:10.1038/nri1886 · Cited by 1,030
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Jensen, S., & Thomsen, A. R. (2012) · Journal of Virology · doi:10.1128/jvi.05738-11 · Cited by 604
Cited by
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Pomeroy, E. J., Hunzeker, J. T., Kluesner, M. G., Lahr, W. S., Smeester, B. A., Crosby, M. R., Lonetree, C.-L., Yamamoto, K., Bendzick, L., Miller, J. S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.009 · Cited by 195
Self-citationB cells engineered to express pathogen-specific antibodies protect against infection
Moffett, H. F., Harms, C. K., Fitzpatrick, K. S., Tooley, M. R., Boonyaratanakornkit, J. B., & Taylor, J. J. (2019) · Science Immunology · doi:10.1126/sciimmunol.aax0644 · Cited by 151
Reprogramming the antigen specificity of B cells using genome-editing technologies
Voss, J. E., González-Martín, A., Andrabi, R., Fuller, R. P., Murrell, B., McCoy, L. E., Porter, K., Huang, D., Li, W., Sok, D., et al. (2019) · eLife · doi:10.7554/elife.42995 · Cited by 99
Mo, F., Duan, S., Jiang, X., Yang, X., Hou, X., Shi, W., Jumbo, J. C. C., Liu, A., Yin, S., Wang, W., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00462-1 · Cited by 86
Akram, F., Sahreen, S., Aamir, F., Haq, I. U., Malik, K. A., Imtiaz, M., Naseem, W., Nasir, N., & Waheed, H. M. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00501-4 · Cited by 83
Metadata
- Authors
- Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Moriarity, Branden S.
- Venue
- Scientific Reports
- Published
- 2018-08-14
- Volume
- 8
- Issue
- 1
- Pages
- 12144-12144
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6092381
- OpenAlex
- W2950101654
- Cited by
- 92
- References
- 41
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 15 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 12 · 2019: 10
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Cancer Institute (P30CA077598)
- National Institute of Allergy and Infectious Diseases (R21AI128087)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9 genome editing, electroporation, B cell expansion, naive B cells, AAVS1 safe harbor, AAV6, site-specific integration, Cas9, antibody production, gene therapy
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, B-Lymphocytes, Cells, Cultured, Endonucleases, Genetic Engineering, Humans, Electroporation, Antigens, CD19, Gene Knockout Techniques, Cell Engineering, Primary Cell Culture, CRISPR-Cas Systems, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. https://app.cochat.ai/papers/10.1038/s41598-018-30358-0
- The paper
- Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S. (2018). Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific Reports. https://doi.org/10.1038/s41598-018-30358-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.